PRIMEX-PHARMACEUTICALS

Primex Pharmaceuticals: New Acquisition Brings an Innovative Oral Solution for Pediatric Anesthesiology to the Market

Swiss pharmaceutical company Primex Pharmaceuticals AG and French
pharmaceutical laboratory Advicenne SA announced today a deal where
Primex will acquire global rights for an advanced oral pharmaceutical
candidate for pediatric anesthesiology developed by Advicenne. The
market potential is evaluated as hundreds of millions of euros.

This oral solution is dedicated to pediatric anesthesiology. Nearly
10,000 patients have already been successfully treated by the university
hospital at Amiens, which collaborated with Advicenne.

With this acquisition, Primex Pharmaceuticals expands its anesthesiology
portfolio with a unique product that will be distributed through
Primex’s existing channels and new partners, which will be appointed in
all other markets.

“This is a breakthrough in the area of pediatric anesthesia, and along
with further applications, the annual market potential is between 100 M€
and 350 M€”, says Kari Sarvanto, President of Primex Pharmaceuticals.
“We’re extremely enthusiastic about the cooperation with Advicenne and
looking forward to bringing such a patient-friendly novel product to the
market.”

“As one of the very first in-house developed products, this deal
validates our strategy and capabilities in developing original
pediatric-adapted drugs”, says Dr Luc-André Granier, CEO of Advicenne.
“Primex Pharmaceuticals is probably the best partner for the commercial
success of the product as its network is global and its commitment for
anesthesiology is very strong.”

Advicenne, a fast-growing specialty pharma, focuses on innovative
pediatric medications, targeting orphan or neglected diseases within the
fields of neurology and nephrology and aims to become a world leader in
those therapeutic areas.

The company has today a strong portfolio of products in late-stage
development targeting critical unmet needs in nephrology and epilepsy,
and has started its commercial activities late 2015 with its first
product on the French market.

About Primex Pharmaceuticals

Primex Pharmaceuticals is a fast-growing company spearheading a new
pharmaceutical business model. It supplies high-quality anesthetics and
life-saving medicines to healthcare institutions and professionals
around the world. Primex’s distribution reaches a population of nearly
one billion people. The company is headquartered in Finland and
Switzerland.